Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography

Andrea I. Guaricci, Joanne D. Schuijf, Filippo Cademartiri, Natale Daniele Brunetti, Deodata Montrone, Erica Maffei, Carlo Tedeschi, Riccardo Ieva, Luigi Di Biase, Massimo Midiri, Luca MacArini, Matteo Di Biase

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of ivabradine could be an attractive alternative to beta-blockade to reduce HR. Methods: One-hundred-twenty-three patients referred for CTCA were prospectively enrolled. Patients were divided in two groups depending on the absence or presence of chronic beta-blockade treatment. Within the two groups patients were randomized to either no additional premedication or oral ivabradine for 5 days prior to CTCA. In presence of chronic beta-blockade therapy it was shifted to atenolol 50 mg twice a day for 5 days prior to CTCA. HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). The target HR was < 65 bpm. Results: Ivabradine significantly reduced HR during CTCA. Mean relative HR reduction was 15% for controls, 12% for chronic beta-blockade, 19% for ivabradine and 24% for both chronic beta-blockade and ivabradine at T2 (p for trend < 0.001). The rate of patients who reached the target HR at T2 was 83% in controls, 71% with chronic beta-blockade, 97% with ivabradine and 97% with both (p for trend < 0.05). The percentage of patients that needed additional IV beta-blockade at T1 decreased from 69% to 40% with ivabradine and 30% with both (p for trend < 0.05). Conclusions: Ivabradine is safe and effective in increasing the rate of patients at target HR and in reducing the need for additional IV beta-blockade in patients referred for CTCA.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalInternational Journal of Cardiology
Volume156
Issue number1
DOIs
StatePublished - Apr 5 2012
Externally publishedYes

Fingerprint

ivabradine
Coronary Angiography
Heart Rate
Safety
Atenolol
Premedication
Computed Tomography Angiography

Keywords

  • Computed tomography coronary angiography
  • Coronary heart disease
  • Heart rate reduction
  • Ivabradine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Guaricci, A. I., Schuijf, J. D., Cademartiri, F., Brunetti, N. D., Montrone, D., Maffei, E., ... Di Biase, M. (2012). Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. International Journal of Cardiology, 156(1), 28-33. https://doi.org/10.1016/j.ijcard.2010.10.035

Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. / Guaricci, Andrea I.; Schuijf, Joanne D.; Cademartiri, Filippo; Brunetti, Natale Daniele; Montrone, Deodata; Maffei, Erica; Tedeschi, Carlo; Ieva, Riccardo; Di Biase, Luigi; Midiri, Massimo; MacArini, Luca; Di Biase, Matteo.

In: International Journal of Cardiology, Vol. 156, No. 1, 05.04.2012, p. 28-33.

Research output: Contribution to journalArticle

Guaricci, AI, Schuijf, JD, Cademartiri, F, Brunetti, ND, Montrone, D, Maffei, E, Tedeschi, C, Ieva, R, Di Biase, L, Midiri, M, MacArini, L & Di Biase, M 2012, 'Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography', International Journal of Cardiology, vol. 156, no. 1, pp. 28-33. https://doi.org/10.1016/j.ijcard.2010.10.035
Guaricci, Andrea I. ; Schuijf, Joanne D. ; Cademartiri, Filippo ; Brunetti, Natale Daniele ; Montrone, Deodata ; Maffei, Erica ; Tedeschi, Carlo ; Ieva, Riccardo ; Di Biase, Luigi ; Midiri, Massimo ; MacArini, Luca ; Di Biase, Matteo. / Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. In: International Journal of Cardiology. 2012 ; Vol. 156, No. 1. pp. 28-33.
@article{255cfe91797945fbaa0cd0ad934896ea,
title = "Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography",
abstract = "Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of ivabradine could be an attractive alternative to beta-blockade to reduce HR. Methods: One-hundred-twenty-three patients referred for CTCA were prospectively enrolled. Patients were divided in two groups depending on the absence or presence of chronic beta-blockade treatment. Within the two groups patients were randomized to either no additional premedication or oral ivabradine for 5 days prior to CTCA. In presence of chronic beta-blockade therapy it was shifted to atenolol 50 mg twice a day for 5 days prior to CTCA. HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). The target HR was < 65 bpm. Results: Ivabradine significantly reduced HR during CTCA. Mean relative HR reduction was 15{\%} for controls, 12{\%} for chronic beta-blockade, 19{\%} for ivabradine and 24{\%} for both chronic beta-blockade and ivabradine at T2 (p for trend < 0.001). The rate of patients who reached the target HR at T2 was 83{\%} in controls, 71{\%} with chronic beta-blockade, 97{\%} with ivabradine and 97{\%} with both (p for trend < 0.05). The percentage of patients that needed additional IV beta-blockade at T1 decreased from 69{\%} to 40{\%} with ivabradine and 30{\%} with both (p for trend < 0.05). Conclusions: Ivabradine is safe and effective in increasing the rate of patients at target HR and in reducing the need for additional IV beta-blockade in patients referred for CTCA.",
keywords = "Computed tomography coronary angiography, Coronary heart disease, Heart rate reduction, Ivabradine",
author = "Guaricci, {Andrea I.} and Schuijf, {Joanne D.} and Filippo Cademartiri and Brunetti, {Natale Daniele} and Deodata Montrone and Erica Maffei and Carlo Tedeschi and Riccardo Ieva and {Di Biase}, Luigi and Massimo Midiri and Luca MacArini and {Di Biase}, Matteo",
year = "2012",
month = "4",
day = "5",
doi = "10.1016/j.ijcard.2010.10.035",
language = "English (US)",
volume = "156",
pages = "28--33",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography

AU - Guaricci, Andrea I.

AU - Schuijf, Joanne D.

AU - Cademartiri, Filippo

AU - Brunetti, Natale Daniele

AU - Montrone, Deodata

AU - Maffei, Erica

AU - Tedeschi, Carlo

AU - Ieva, Riccardo

AU - Di Biase, Luigi

AU - Midiri, Massimo

AU - MacArini, Luca

AU - Di Biase, Matteo

PY - 2012/4/5

Y1 - 2012/4/5

N2 - Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of ivabradine could be an attractive alternative to beta-blockade to reduce HR. Methods: One-hundred-twenty-three patients referred for CTCA were prospectively enrolled. Patients were divided in two groups depending on the absence or presence of chronic beta-blockade treatment. Within the two groups patients were randomized to either no additional premedication or oral ivabradine for 5 days prior to CTCA. In presence of chronic beta-blockade therapy it was shifted to atenolol 50 mg twice a day for 5 days prior to CTCA. HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). The target HR was < 65 bpm. Results: Ivabradine significantly reduced HR during CTCA. Mean relative HR reduction was 15% for controls, 12% for chronic beta-blockade, 19% for ivabradine and 24% for both chronic beta-blockade and ivabradine at T2 (p for trend < 0.001). The rate of patients who reached the target HR at T2 was 83% in controls, 71% with chronic beta-blockade, 97% with ivabradine and 97% with both (p for trend < 0.05). The percentage of patients that needed additional IV beta-blockade at T1 decreased from 69% to 40% with ivabradine and 30% with both (p for trend < 0.05). Conclusions: Ivabradine is safe and effective in increasing the rate of patients at target HR and in reducing the need for additional IV beta-blockade in patients referred for CTCA.

AB - Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of ivabradine could be an attractive alternative to beta-blockade to reduce HR. Methods: One-hundred-twenty-three patients referred for CTCA were prospectively enrolled. Patients were divided in two groups depending on the absence or presence of chronic beta-blockade treatment. Within the two groups patients were randomized to either no additional premedication or oral ivabradine for 5 days prior to CTCA. In presence of chronic beta-blockade therapy it was shifted to atenolol 50 mg twice a day for 5 days prior to CTCA. HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). The target HR was < 65 bpm. Results: Ivabradine significantly reduced HR during CTCA. Mean relative HR reduction was 15% for controls, 12% for chronic beta-blockade, 19% for ivabradine and 24% for both chronic beta-blockade and ivabradine at T2 (p for trend < 0.001). The rate of patients who reached the target HR at T2 was 83% in controls, 71% with chronic beta-blockade, 97% with ivabradine and 97% with both (p for trend < 0.05). The percentage of patients that needed additional IV beta-blockade at T1 decreased from 69% to 40% with ivabradine and 30% with both (p for trend < 0.05). Conclusions: Ivabradine is safe and effective in increasing the rate of patients at target HR and in reducing the need for additional IV beta-blockade in patients referred for CTCA.

KW - Computed tomography coronary angiography

KW - Coronary heart disease

KW - Heart rate reduction

KW - Ivabradine

UR - http://www.scopus.com/inward/record.url?scp=84858078785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858078785&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.10.035

DO - 10.1016/j.ijcard.2010.10.035

M3 - Article

VL - 156

SP - 28

EP - 33

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -